Central Analgesic Drugs for the Treatment of Chronic Pain
Unknown statusNCT02223442
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic pain is defined as pain that persists after healing of the wound that caused it, and can occur even in the absence of any obvious pathological trigger. In our country, there is a growing interest in the proper management of the disease "pain". Pain is also the first symptom of the disease in 20 -50% of patients with neoplastic disease and from 75% to 90% of patients with advanced cancer suffers from chronic pain . However, pain management is mostly inadequate. This study aims to assess the Italian clinical practice in reference to the pharmacological management of chronic pain by health professionals involved in the treatment of pain in some centers belonging to the Italian network of pain therapy.
Study details
- Official title
- Cognitive Study on the Use of Central Analgesic Drugs in the Management of Chronic Pain
- Conditions
- Sponsor
- University of Parma
- Start date
- 2014-09
- Primary completion
- 2016-02
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Males and females over the age of 18 years * Chronic neuropathic and / or nociceptive and / or mixed pain, whereby clinicians considers necessary to start opioid therapy * Signed informed consent Exclusion Criteria: * Males and females aged under 18 years * Patients already receiving opioid analgesic drugs or drugs of the class MOR-NRI. * Taking abuse drugs or alcohol abuse * Patients with contraindications to the use of central analgesic drugs * Patients who refuse participation * Prior cognitive impairment or mental retardation * Severe immunodeficiency (WBC \<4,000) * Severe renal impairment (serum creatinine \> 2g/dl or Creatinine clearance \<30 ml / h) * Hepatic impairment (Cholinesterase \<2.000UI or INR\> 2)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02223442